Comparative Pharmacology
Head-to-head clinical analysis: ALOXI versus ONDANSETRON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALOXI versus ONDANSETRON.
ALOXI vs Ondansetron
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin 5-HT3 receptor antagonist; blocks serotonin binding at 5-HT3 receptors in the chemoreceptor trigger zone and gastrointestinal tract, preventing nausea and vomiting.
Selective serotonin 5-HT3 receptor antagonist; blocks serotonin binding at 5-HT3 receptors in the chemoreceptor trigger zone and gastrointestinal tract, reducing nausea and vomiting.
0.25 mg intravenously over 30 seconds, administered 30 minutes before chemotherapy on day 1 of each cycle; not to be repeated within 7 days.
8 mg orally or intravenously every 8 hours as needed, or 32 mg IV single dose prior to chemotherapy; maximum 24 mg IV single dose for prevention of postoperative nausea and vomiting.
None Documented
None Documented
Clinical Note
moderateOndansetron + Norfloxacin
"Ondansetron may increase the QTc-prolonging activities of Norfloxacin."
Clinical Note
moderateOndansetron + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Ondansetron is combined with Fluticasone propionate."
Clinical Note
moderateOndansetron + Haloperidol
"Ondansetron may increase the QTc-prolonging activities of Haloperidol."
Clinical Note
moderateOndansetron + Ibandronate
Terminal elimination half-life is approximately 40 hours (range 33–45 hours) in adults, allowing once-daily dosing for prevention of chemotherapy-induced nausea and vomiting.
Terminal elimination half-life is approximately 3-6 hours in adults; may be prolonged to 8-15 hours in elderly or severe hepatic impairment (Child-Pugh Class C).
Renal (approximately 50% unchanged drug), biliary/fecal (approximately 35% as metabolites). Total clearance is 160 ± 38 mL/min.
Approximately 5% of the dose is excreted unchanged in urine, while the majority is metabolized hepatically via CYP1A2, CYP2D6, and CYP3A4. About 90% is eliminated as metabolites in urine (48%) and feces (42%).
Category C
Category C
5-HT3 Antagonist
5-HT3 Antagonist
"Ondansetron may increase the QTc-prolonging activities of Ibandronate."